Pharmaceutical compositions for combination therapy

1. A combination product comprising:

(i) a compound selected from the group consisting of NTZ, tizoxanide, and a pharmaceutically acceptable salt thereof; and

(ii) at least one PPAR agonist selected from the group consisting of Elafibranor, Seladelpar, Saroglitazar, Lanifibranor, and a pharmaceutical salt thereof.

2. The combination product according to claim 1 , comprising:

(i) a compound selected from the group consisting of nitazoxanide, and a pharmaceutical salt thereof; and

(ii) Elafibranor or a pharmaceutically acceptable salt thereof.

3. The combination product according to claim 1 , further comprising a pharmaceutically acceptable carrier.

4. The combination product according to claim 1 , wherein the combination product is a kit for sequential, separate or simultaneous use.

5. The combination product according to claim 1 , further comprising at least one therapeutically active agent with known antifibrotic activity selected from the group consisting of:

pirfenidone;

receptor tyrosine kinase inhibitors (RTKIs);

angiotensin II (AT1) receptor blockers;

CTGF inhibitors;

activators of the latent TGFβ complex;

TGFβ receptors type I (TGFBRI) or type II (TGFBRII) and their ligands;

auxiliary co-receptors or type III receptors;

components of the SMAD-dependent canonical pathway;

members of the SMAD-independent or non-canonical pathways;

canonical and non-canonical Hedgehog signaling pathways;

members of the WNT Notch pathways which are susceptible to influence by TGFβ.

6. The combination product according to claim 1 , further comprising at least one therapeutically active agent selected from JAK/STAT inhibitors and other anti-inflammatory and/or immunosuppressant agents.

7. The combination product according to claim 6 , wherein the therapeutically active agent is selected from glucocorticoids, NSAIDS, cyclophosphamide, nitrosoureas, folic acid analogs, purine analogs, pyrimidine analogs, methotrexate, azathioprine, mercaptopurine, ciclosporin, myriocin, tacrolimus, sirolimus, mycophenolic acid derivatives, fingolimod and other sphingosine-1-phosphate receptor modulators, monoclonal and/or polyclonal antibodies against such targets as proinflammatory cytokines and proinflammatory cytokine receptors, T-cell receptor and integrins.

8. The combination product according to claim 1 , wherein components (i) and (ii) are formulated in an injectable suspension, a gel, an oil, a pill, a tablet, a suppository, a powder, a capsule, an aerosol, an ointment, a cream, a patch, or means of galenic forms for a prolonged and/or slow release.

9. A composition comprising the combination product according to claim 1 .

10. The combination product according to claim 5 , wherein the at least one therapeutically active agent is selected from the group consisting of:

Nintedanib,

Sorafenib;

activators of the latent TGFβ complex selected from MMP2, MMP9 and THBS1;

TGFβ;

Activin;

inhibin;

Nodal;

anti-Müllerian hormone;

GDFs

BMPs; and

Hh ligands or target genes.